comparemela.com
  1. Home
  2. Live Updates
  3. Atient Gsk Gb00bn7swp63 - Breaking News

Atient Gsk Gb00bn7swp63 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GSK : Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone

72% and 36% reduction in the risk of disease progression or death observed in the dMMR/MSI-H population and overall patient population, respectively Clinically. | March 27, 2023

Hesham abdullahGlobal head of oncology developmentThenew england journalSenior vice presidentGlobal headOncology developmentGsk plc stock exchangePress releaseAtient gsk gb00bn7swp63

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.